The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics

Nature Reviews Gastroenterology and Hepatology

Volumn 17, Issue 11, 2020, Pages 687-701

  Swanson, Kelly S ^a   Gibson, Glenn R ^b   Hutkins, Robert ^c   Reimer, Raylene A ^d   Reid, Gregor ^e   Verbeke, Kristin ^f,g   Scott, Karen P ^h   Holscher, Hannah D ^a   Azad, Meghan B ⁱ   Delzenne, Nathalie M ^j   Sanders, Mary Ellen ^k  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF READING   (United Kingdom)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g LEUVEN FOOD SCIENCE AND NUTRITION RESEARCH CENTRE LFORCE   (Belgium)

^h ROWETT RESEARCH INSTITUTE   (United Kingdom)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

^j UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^k International Scientific Association for Probiotics and Prebiotics   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; FRUCTOSE OLIGOSACCHARIDE; GALACTOSE OLIGOSACCHARIDE; INULIN; LITESSE ULTRA POLYDEXTROSE; PECTIN; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT; UNCLASSIFIED DRUG;

ANTAGONISTIC EFFECT; CHICORY; CLINICAL EFFECTIVENESS; CONSENSUS; DRUG MECHANISM; DRUG SAFETY; HUMAN; INTERSECTORAL COLLABORATION; MEDICAL TERMINOLOGY; MICROBIAL COLONIZATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAKEHOLDER ENGAGEMENT; SYMBIOSIS; CONSENSUS DEVELOPMENT;

HUMANS; PREBIOTICS; PROBIOTICS; SYNBIOTICS;

EID: 85089743727     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/s41575-020-0344-2     Document Type: Review

References (129)

1. Coyte, K. Z., Schluter, J. & Foster, K. R. The ecology of the microbiome: networks, competition, and stability. Science 350, 663–666 (2015).
2. Walker, A. W. & Lawley, T. D. Therapeutic modulation of intestinal dysbiosis. Pharmacol. Res. 69, 75–86 (2013).
3. Deehan, E. C. et al. Modulation of the gastrointestinal microbiome with nondigestible fermentable carbohydrates to improve human health. Microbiol. Spectr. 10.1128/microbiolspec.BAD-0019-2017 (2017). DOI: 10.1128/microbiolspec.BAD-0019-2017
4. Cani, P. D. Human gut microbiome: hopes, threats and promises. Gut 67, 1716–1725 (2018).
5. Gibson, G. R. & Roberfroid, M. B. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J. Nutr. 125, 1401–1412 (1995).
6. Andriulli, A. et al. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J. Clin. Gastroenterol. 42, S218–S223 (2008).
7. Cappello, C., Tremolaterra, F., Pascariello, A., Ciacci, C. & Iovino, P. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): effects on symptoms, colonic transit and quality of life. Int. J. Colorectal Dis. 28, 349–358 (2013).
8. Martin, R. & Langella, P. Emerging health concepts in the probiotics field: streamlining the definitions. Front. Microbiol. 10, 1047 (2019).
9. Oliveira, R. P. et al. Effect of different prebiotics on the fermentation kinetics, probiotic survival and fatty acids profiles in nonfat symbiotic fermented milk. Int. J. Food Microbiol. 128, 467–472 (2009).
10. Collado, M. C., Vinderola, G. & Salminen, S. Postbiotics: facts and open questions. A position paper on the need for a consensus definition. Benef. Microbes 10, 711–719 (2019).
11. Shanahan, F. & Collins, S. M. Pharmabiotic manipulation of the microbiota in gastrointestinal disorders, from rationale to reality. Gastroenterol. Clin. North. Am. 39, 721–726 (2010).
12. Hill, C. et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506–514 (2014). Important paper updating the probiotic concept.
13. Gibson, G. R. et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 14, 491–502 (2017). Important paper updating the prebiotic concept. Paper includes the author who first introduced the concept of ‘prebiotics’.
14. Kolida, S. & Gibson, G. R. Synbiotics in health and disease. Annu. Rev. Food Sci. Technol. 2, 373–393 (2011). This article acknowledges the importance of differentiating between two distinct types of synbiotic: the complementary synbiotic (microbial and substrate components act independently) and the synergistic synbiotic (the substrate component is chosen to support the growth of the microbial component). Differentiating synbiotics in this way ensures that the development of synbiotics is not constrained in any way and indeed encourages innovation.
15. Krumbeck, J. A., Walter, J. & Hutkins, R. W. Synbiotics for improved human health: Recent developments, challenges, and opportunities. Annu. Rev. Food Sci. Technol. 9, 451–479 (2018).
16. Gerardo, N. & Hurst, G. Q&A: friends (but sometimes foes) within: the complex evolutionary ecology of symbioses between host and microbes. BMC Biol. 15, 126 (2017).
17. Srivastava, A. & Mishra, S. Enrichment and evaluation of galacto-oligosaccharides produced by whole cell treatment of sugar reaction mixture. Mol. Biol. Rep. 46, 1181–1188 (2019).
18. Porras-Dominguez, J. R. et al. Frucooligosaccharides purification: complexing simple sugars with phenylboronic acid. Food Chem. 285, 204–212 (2019).
19. Crittenden, R. G. & Playne, M. J. Production, properties and applications of food-grade oligosaccharides. Trends Food Sci. Technol. 7, 353–361 (1996).
20. Jackson, S. A. et al. Improving end-user trust in the quality of commercial probiotic products. Front. Microbiol. 10, 739 (2019).
21. Krumbeck, J. A. et al. Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics. Microbiome 6, 121 (2018). In this paper, a synbiotic consisting of Bifidobacterium strains and galactooligosaccharides did not demonstrate functional synergism but showed that the microorganism and fermentative substrate components by themselves improved the markers of colonic permeability.
22. Hadi, A., Alizadeh, K., Hajianfar, H., Mohammadi, H. & Miraghajani, M. Efficacy of synbiotic supplementation in obesity treatment: a systematic review and meta-analysis of clinical trials. Crit. Rev. Food Sci. Nutr. 60, 584–596 (2020).
23. Mahboobi, S., Rahimi, F. & Jafarnejad, S. Effects of prebiotic and synbiotic supplementation on glycaemia and lipid profile in type 2 diabetes: a meta-analysis of randomized controlled trials. Adv. Pharm. Bull. 8, 565–574 (2018).
24. Nikbakht, E. et al. Effect of probiotics and synbiotics on blood glucose: a systematic review and meta-analysis of controlled trials. Eur. J. Nutr. 57, 95–106 (2018).
25. Sharpton, S. R., Maraj, B., Harding-Theobald, E., Vittinghoff, E. & Terrault, N. A. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am. J. Clin. Nutr. 110, 139–149 (2019).
26. Hadi, A., Mohammadi, H., Miraghajani, M. & Ghaedi, E. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. Crit. Rev. Food Sci. Nutr. 59, 2494–2505 (2019).
27. Ford, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M. & Moayyedi, P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment. Pharmacol. Ther. 48, 1044–1060 (2018).
28. Skonieczna-Zydecka, K. et al. A systematic review, meta-analysis, and meta-regression evaluating the efficacy and mechanisms of action of probiotics and synbiotics in the prevention of surgical site infections and surgery-related complications. J. Clin. Med. 7, 556 (2018).
29. Kasatpibal, N. et al. Effectiveness of probiotic, prebiotic, and synbiotic therapies in reducing postoperative complications: a systematic review and network meta-analysis. Clin. Infect. Dis. 64 (Suppl. 2), S153–S160 (2017).
30. McFarlane, C., Ramos, C. I., Johnson, D. W. & Campbell, K. L. Prebiotic, probiotic, and synbiotic supplementation in chronic kidney disease: a systematic review and meta-analysis. J. Ren. Nutr. 29, 209–220 (2019).
31. Pisano, A., D’Arrigo, G., Coppolino, G. & Bolignano, D. Biotic supplements for renal patients: a systematic review and meta-analysis. Nutrients 10, 1224 (2018).
32. Chang, Y. S. et al. Synbiotics for prevention and treatment of a dermatitis: a meta-analysis of randomized clinical trials. JAMA Pediatr. 170, 236–242 (2016). This meta-analysis provides evidence that supports the use of synbiotics for the treatment of atopic dermatitis, which is thought to be associated with altered gut microbiota that promote an environment that is more susceptible to allergic disease.
33. Wu, X. D., Liu, M. M., Liang, X., Hu, N. & Huang, W. Effects of perioperative supplementation with pro-/synbiotics on clinical outcomes in surgical patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Clin. Nutr. 37, 505–515 (2018).
34. Liu, L., Li, P., Liu, Y. & Zhang, Y. Efficacy of probiotics and synbiotics in patients with nonalcoholic fatty liver disease: a meta-analysis. Dig. Dis. Sci. 64, 3402–3412 (2019). This meta-analysis highlights the benefits of synbiotics for the hallmarks of non-alcoholic fatty liver disease, liver steatosis, liver enzymes, lipid profiles and liver stiffness.
35. Chan, C. K. Y., Tao, J., Chan, O. S., Li, H. B. & Pang, H. Preventing respiratory tract infections by synbiotic interventions: A systematic review and meta-analysis of randomized controlled trials. Adv. Nutr. 10.1093/advances/nmaa003 (2020). DOI: 10.1093/advances/nmaa003
36. Clarke, M. & Chalmers, I. Reflections on the history of systematic reviews. BMJ Evid. Based Med. 23, 121–122 (2018).
37. Institute of Medicine. Finding what works in health care: standards for systematic reviews (The National Academies Press, 2011).
38. World Health Organization. WHO Handbook for Guideline Development (WHO, 2014).
39. Komatsu, S. et al. Efficacy of perioperative synbiotics treatment for the prevention of surgical site infection after laparoscopic colorectal surgery: a randomized controlled trial. Surg. Today 46, 479–490 (2016).
40. Anderson, A. D., McNaught, C. E., Jain, P. K. & MacFie, J. Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut 53, 241–245 (2004).
41. Sergeev, I. N., Aljutaily, T., Walton, G. & Huarte, E. Effects of synbiotic supplement on human gut microbiota, body composition and weight loss in obesity. Nutrients 12, 222 (2020).
42. Nabhani, Z., Hezaveh, S. J. G., Razmpoosh, E., Asghari-Jafarabadi, M. & Gargari, B. P. The effects of synbiotic supplementation on insulin resistance/sensitivity, lipid profile and total antioxidant capacity in women with gestational diabetes mellitus: a randomized double blind placebo controlled clinical trial. Diabetes Res. Clin. Pract. 138, 149–157 (2018).
43. Ustundag, G. H., Altuntas, H., Soysal, Y. D. & Kokturk, F. The effects of synbiotic “Bifidobacterium lactis B94 plus inulin” addition on standard triple therapy of Helicobacter pylori eradication in children. Can. J. Gastroenterol. Hepatol. 2017, 8130596 (2017).
44. Islek, A., Sayar, E., Yilmaz, A. & Artan, R. Bifidobacterium lactis B94 plus inulin for Treatment of Helicobacter pylori infection in children: does it increase eradication rate and patient compliance? Acta Gastroenterol. Belg. 78, 282–286 (2015).
45. Sommacal, H. M., Bersch, V. P., Vitola, S. P. & Osvaldt, A. B. Perioperative synbiotics decrease postoperative complications in periampullary neoplasms: a randomized, double-blind clinical trial. Nutr. Cancer 67, 457–462 (2015).
46. Stenman, L. K. et al. Probiotic with or without fiber controls body fat mass, associated with serum zonulin, in overweight and obese adults-randomized controlled trial. EBioMedicine 13, 190–200 (2016).
47. Maldonado-Gomez, M. X. et al. Stable engraftment of Bifidobacterium longum AH1206 in the human gut depends on individualized features of the resident microbiome. Cell Host Microbe 20, 515–526 (2016).
48. Moher, D. et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int. J. Surg. 10, 28–55 (2012).
49. Klurfeld, D. M. et al. Considerations for best practices in studies of fiber or other dietary components and the intestinal microbiome. Am. J. Physiol. Endocrinol. Metab. 315, E1087–E1097 (2018).
50. Likotrafiti, E., Tuohy, K. M., Gibson, G. R. & Rastall, R. A. An in vitro study of the effect of probiotics, prebiotics and synbiotics on the elderly faecal microbiota. Anaerobe 27, 50–55 (2014).
51. Pham, V. T. & Mohajeri, M. H. The application of in vitro human intestinal models on the screening and development of pre- and probiotics. Benef. Microbes 9, 725–742 (2018).
52. Aabed, K. et al. Ameliorative effect of probiotics (Lactobacillus paracaseii and Protexin(R)) and prebiotics (propolis and bee pollen) on clindamycin and propionic acid-induced oxidative stress and altered gut microbiota in a rodent model of autism. Cell Mol. Biol. 65, 1–7 (2019).
53. Ferrarese, R., Ceresola, E. R., Preti, A. & Canducci, F. Probiotics, prebiotics and synbiotics for weight loss and metabolic syndrome in the microbiome era. Eur. Rev. Med. Pharmacol. Sci. 22, 7588–7605 (2018).
54. Tzortzis, G., Baillon, M. L., Gibson, G. R. & Rastall, R. A. Modulation of anti-pathogenic activity in canine-derived Lactobacillus species by carbohydrate growth substrate. J. Appl. Microbiol. 96, 552–559 (2004).
55. Sanders, M. E. et al. Effects of genetic, processing, or product formulation changes on efficacy and safety of probiotics. Ann. NY Acad. Sci. 1309, 1–18 (2014).
56. Meance, S. et al. Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Microb. Ecol. Health Dis. 15, 15–22 (2003).
57. Dethlefsen, L. & Relman, D. A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. USA 108, 4554–4561 (2011).
58. Modi, S. R., Collins, J. J. & Relman, D. A. Antibiotics and the gut microbiota. J. Clin. Invest. 124, 4212–4218 (2014).
59. Le Bastard, Q. et al. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment. Pharmacol. Ther. 47, 332–345 (2018).
60. David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).
61. U.S. Food and Drug Administration. Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-evidence-based-review-system-scientific-evaluation-health-claims (2009).
62. Davis, L. M., Martinez, I., Walter, J. & Hutkins, R. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int. J. Food Microbiol. 144, 285–292 (2010).
63. Donaldson, G. P. et al. Gut microbiota utilize immunoglobulin A for mucosal colonization. Science 360, 795–800 (2018).
64. Cardarelli, H. R. et al. In vitro fermentation of prebiotic carbohydrates by intestinal microbiota in the presence of Lactobacillus amylovorus DSM 16998. Benef. Microbes 7, 119–133 (2016).
65. Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K. & Knight, R. Diversity, stability and resilience of the human gut microbiota. Nature 489, 220–230 (2012).
66. Holmes, E., Li, J. V., Marchesi, J. R. & Nicholson, J. K. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab. 16, 559–564 (2012).
67. Earle, K. A. et al. Quantitative imaging of gut microbiota spatial organization. Cell Host Microbe 18, 478–488 (2015).
68. Lloyd-Price, J., Abu-Ali, G. & Huttenhower, C. The healthy human microbiome. Genome Med. 8, 51 (2016).
69. Closa-Monasterolo, R. et al. Safety and efficacy of inulin and oligofructose supplementation in infant formula: results from a randomized clinical trial. Clin. Nutr. 32, 918–927 (2013).
70. Olesen, M. & Gudmand-Hoyer, E. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am. J. Clin. Nutr. 72, 1570–1575 (2000).
71. Lasekan, J., Baggs, G., Acosta, S. & Mackey, A. Soy protein-based infant formulas with supplemental fructooligosaccharides: gastrointestinal tolerance and hydration status in newborn infants. Nutrients 7, 3022–3037 (2015).
72. van den Nieuwboer, M. & Claassen, E. Dealing with the remaining controversies of probiotic safety. Benef. Microbes 10, 605–616 (2019).
73. Sanders, M. E. et al. Probiotic use in at-risk populations. J. Am. Pharm. Assoc. 56, 680–686 (2016).
74. Sanders, M. E. et al. Safety assessment of probiotics for human use. Gut Microbes 1, 164–185 (2010).
75. Ioannidis, J. P. et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann. Intern. Med. 141, 781–788 (2004).
76. Bafeta, A., Koh, M., Riveros, C. & Ravaud, P. Harms reporting in randomized controlled trials of interventions aimed at modifying microbiota: a systematic review. Ann. Intern. Med. 169, 240–247 (2018).
77. van den Nieuwboer, M. et al. The administration of probiotics and synbiotics in immune compromised adults: is it safe? Benef. Microbes 6, 3–17 (2015).
78. van den Nieuwboer, M. et al. Safety of probiotics and synbiotics in children under 18 years of age. Benef. Microbes 6, 615–630 (2015).
79. van den Nieuwboer, M., Claassen, E., Morelli, L., Guarner, F. & Brummer, R. J. Probiotic and synbiotic safety in infants under two years of age. Benef. Microbes 5, 45–60 (2014).
80. NIH National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (2018).
81. Government of Canada. Accepted Claims about the Nature of Probiotic Microorganisms in Food https://www.canada.ca/en/health-canada/services/food-nutrition/food-labelling/health-claims/accepted-claims-about-nature-probiotic-microorganisms-food.html (2009).
82. Governement of Canada. Questions and Answers on Probiotics https://www.canada.ca/en/health-canada/services/food-nutrition/food-labelling/health-claims/questions-answers-probiotics.html (2009).
83. Ministero della Salute y Secretaría de Agricultura, Ganadería y Pesca. Guidelines on Probiotics and Prebiotics [Italian] http://www.salute.gov.it/imgs/C_17_pubblicazioni_1016_ulterioriallegati_ulterioreallegato_0_alleg.pdf (2018).
84. Secretaria de Politicas, Regulacion e Institutos, Ministerio de Salud, Argentina. Codigo Alimentario Argentino [Spanish] http://www.anmat.gov.ar/webanmat/Legislacion/Alimentos/Resolucion_Conjunta_261-2011_y_22-2011.pdf (2011).
85. Departamento Agencia Nacional de Medicamentos, Salud Publica, Gobierno de Chile. Define regimen de control sanitario para productors en formas farmaceutias orales, elaborados con Lactobacillus spp., Bifidobacterium spp. y otros bacilos especificos [Spanish] https://www.carey.cl/download/filebase/newsalert/res-n-3435-probioticos.pdf (2018).
86. Invima. Resolucion 288 de 2008 [Spanish]. http://normograma.invima.gov.co/docs/resolucion_minproteccion_0288_2008.htm (2008).
87. Agencia Nacional de Vigilancia Sanitaria. Guia para instrucao processual de peticao de avaliacao de probiotics para uso em alimentos [Portugese]. http://portal.anvisa.gov.br/documents/10181/5280930/21.pdf/1c99eeb1-7143-469a-93ff-7b2b0f9187c0 (2019).
88. Codex Alimentarius Commission. Joint FAO/WHO Food Standards Programme Codex Committee on Nutrition and Foods for Special Dietary Uses: Forty-first Session http://www.fao.org/fao-who-codexalimentarius/sh-proxy/en/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex%252FMeetings%252FCX-720-41%252FWD%252Fnf41_11e.pdf (2019).
89. Mary Ellen Sanders. Harmonized Probiotic Guidelines to be Discussed at Codex Alimentarius Meeting November 24-29, ISAPP https://isappscience.org/harmonized-probiotic-guidelines-to-be-discussed-at-codex-alimentarius-meeting-november-24-29/ (2019).
90. Food Safety Authority of Ireland. Probiotic Health Claims https://www.fsai.ie/faq/probiotic_health_claims.html (2020).
91. Healey, G. et al. Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study. Br. J. Nutr. 119, 176–189 (2018). This study demonstrated that people with a high dietary fibre intake had a greater gut microbiota response and are therefore more likely to benefit from an inulin-type fructan prebiotic than those with a low dietary fibre intake.
92. Dey, M. Toward a personalized approach in prebiotics research. Nutrients 9, 92 (2017).
93. Walter, J., Armet, A. M., Finlay, B. B. & Shanahan, F. Establishing or exaggerating causality for the gut microbiome: lessons from human microbiota-associated rodents. Cell 180, 221–232 (2020).
94. Rowe, S. et al. Funding food science and nutrition research: financial conflicts and scientific integrity. J. Nutr. 139, 1051–1053 (2009).
95. Alexander, N. et al. Achieving a transparent, actionable framework for public-private partnerships for food and nutrition research. Am. J. Clin. Nutr. 101, 1359–1363 (2015).
96. Kanazawa, H. et al. Synbiotics reduce postoperative infectious complications: a randomized controlled trial in biliary cancer patients undergoing hepatectomy. Langenbecks Arch. Surg. 390, 104–113 (2005).
97. Rammohan, A. et al. Synbiotics in surgery for chronic pancreatitis: are they truly effective? A single-blind prospective control trial. Ann. Surg. 262, 31–37 (2015).
98. Rayes, N. et al. Effect of enteral nutrition and synbiotics on bacterial infection rates after pylorus-preserving pancreatoduodenectomy: a randomized, double-blind trial. Ann. Surg. 246, 36–41 (2007).
99. Reddy, B. S. et al. Randomized clinical trial of effect of synbiotics, neomycin and mechanical bowel preparation on intestinal barrier function in patients undergoing colectomy. Br. J. Surg. 94, 546–554 (2007).
100. Usami, M. et al. Effects of perioperative synbiotic treatment on infectious complications, intestinal integrity, and fecal flora and organic acids in hepatic surgery with or without cirrhosis. J. Parenter. Enter. Nutr. 35, 317–328 (2011).
101. Eslamparast, T. et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am. J. Clin. Nutr. 99, 535–542 (2014).
102. Malaguarnera, M. et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci. 57, 545–553 (2012).
103. Mofidi, F. et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br. J. Nutr. 117, 662–668 (2017).
104. Javadi, L. et al. Pro- and prebiotic effects on oxidative stress and inflammatory markers in non-alcoholic fatty liver disease. Asia Pac. J. Clin. Nutr. 27, 1031–1039 (2018).
105. Panigrahi, P. et al. A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature 548, 407–412 (2017). This paper discussed the use of a synbiotic consisting of Lactobacillus plantarum and fructo-oligosaccharides in a large (4,500 participants) intervention study to protect infants against sepsis.
106. Hibberd, A. A. et al. Probiotic or synbiotic alters the gut microbiota and metabolism in a randomised controlled trial of weight management in overweight adults. Benef. Microbes 10, 121–135 (2019).
107. Eslamparast, T. et al. Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study. Br. J. Nutr. 112, 438–445 (2014).
108. Asemi, Z., Khorrami-Rad, A., Alizadeh, S. A., Shakeri, H. & Esmaillzadeh, A. Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial. Clin. Nutr. 33, 198–203 (2014).
109. Shakeri, H. et al. Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes. Lipids 49, 695–701 (2014).
110. Ahmadi, S., Jamilian, M., Tajabadi-Ebrahimi, M., Jafari, P. & Asemi, Z. The effects of synbiotic supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes: a randomised, double-blind, placebo-controlled trial. Br. J. Nutr. 116, 1394–1401 (2016).
111. Tajabadi-Ebrahimi, M. et al. A randomized controlled clinical trial investigating the effect of synbiotic administration on markers of insulin metabolism and lipid profiles in overweight type 2 diabetic patients with coronary heart disease. Exp. Clin. Endocrinol. Diabetes 125, 21–27 (2017).
112. Maneerat, S. et al. Consumption of Bifidobacterium lactis Bi-07 by healthy elderly adults enhances phagocytic activity of monocytes and granulocytes. J. Nutr. Sci. 2, e44 (2013).
113. Nova, E., Viadel, B., Warnberg, J., Carreres, J. E. & Marcos, A. Beneficial effects of a synbiotic supplement on self-perceived gastrointestinal well-being and immunoinflammatory status of healthy adults. J. Med. Food 14, 79–85 (2011).
114. Soleimani, A. et al. The effects of synbiotic supplementation on metabolic status in diabetic patients undergoing hemodialysis: a randomized, double-blinded, placebo-controlled trial. Probiotics Antimicro. Prot. 11, 1248–1256 (2019).
115. Rogha, M., Esfahani, M. Z. & Zargarzadeh, A. H. The efficacy of a synbiotic containing Bacillus coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol. Hepatol. Bed Bench 7, 156–163 (2014).
116. Basturk, A., Artan, R. & Yilmaz, A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: a randomized controlled trial. Turk. J. Gastroenterol. 27, 439–443 (2016).
117. Shafaghi, A. et al. The effect of probiotic plus prebiotic supplementation on the tolerance and efficacy of Helicobacter pylori eradication quadruple therapy: a randomized prospective double blind controlled trial. Middle East J. Dig. Dis. 8, 179–188 (2016).
118. Sirvan, B. N., Usta, M. K., Kizilkan, N. U. & Urganci, N. Are synbiotics added to the standard therapy to eradicate Helicobacter pylori in children beneficial? A randomized controlled study. Euroasian J. Hepatogastroenterol. 7, 17–22 (2017).
119. Samimi, M. et al. The effects of synbiotic supplementation on metabolic status in women with polycystic ovary syndrome: a randomized double-blind clinical trial. Probiotics Antimicrob. Prot. 11, 1355–1361 (2019).
120. Nasri, K. et al. The effects of synbiotic supplementation on hormonal status, biomarkers of inflammation and oxidative stress in subjects with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. BMC Endocr. Disord. 18, 21 (2018).
121. Guida, B. et al. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. Nutr. Metab. Cardiovasc. Dis. 24, 1043–1049 (2014).
122. Dehghani, H., Heidari, F., Mozaffari-Khosravi, H., Nouri-Majelan, N. & Dehghani, A. Synbiotic supplementations for azotemia in patients with chronic kidney disease: a randomized controlled trial. Iran. J. Kidney Dis. 10, 351–357 (2016).
123. Rossi, M. et al. Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial. Clin. J. Am. Soc. Nephrol. 11, 223–231 (2016).
124. Kukkonen, K. et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 119, 192–198 (2007).
125. Gerasimov, S. V., Vasjuta, V. V., Myhovych, O. O. & Bondarchuk, L. I. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. Am. J. Clin. Dermatol. 11, 351–361 (2010).
126. Farid, R., Ahanchian, H., Jabbari, F. & Moghiman, T. Effect of a new synbiotic mixture on atopic dermatitis in children: a randomized-controlled trial. Iran. J. Pediatr. 21, 225–230 (2011).
127. Wu, K. G., Li, T. H. & Peng, H. J. Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. Br. J. Dermatol. 166, 129–136 (2012).
128. Childs, C. E. et al. Xylo-oligosaccharides alone or in synbiotic combination with Bifidobacterium animalis subsp. lactis induce bifidogenesis and modulate markers of immune function in healthy adults: a double-blind, placebo-controlled, randomised, factorial cross-over study. Br. J. Nutr. 111, 1945–1956 (2014).
129. Favretto, D. C., Pontin, B. & Moreira, T. R. Effect of the consumption of a cheese enriched with probiotic organisms (Bifidobacterium lactis Bi-07) in improving symptoms of constipation. Arq. Gastroenterol. 50, 196–201 (2013).